Favaretto, A., F. Grossi, A. Morabito, and R. Ravasio. “Costs of Adverse Events Associated With Afatinib, Erlotinib, and Gefitinib First-Line Therapies in Advanced Non-Small-Cell Lung Cancer Harboring EGFR-Activating Mutations: Il Costo Degli Eventi Avversi Associati Ad Afatinib, Erlotinib E Gefitinib Nel Trattamento Del Tumore Del Polmone Non a Piccole Cellule Con Mutazione EGFR”. Global and Regional Health Technology Assessment, vol. 4, no. 1, July 2017, pp. 187-96, doi:10.33393/grhta.2017.394.